Compare Sana Biotechnology Inc (SANA) vs Southern Copper Corp (SCCO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Southern Copper Corp — how do they compare? Sana Biotechnology Inc trades at $3.79 (market cap $1.13B), while Southern Copper Corp trades at $194.56 (market cap $164.21B). The key difference: Southern Copper Corp is far larger — about 145.3× Sana Biotechnology Inc's market cap, and Southern Copper Corp pays a 2.26% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| SANA | SCCO | |
|---|---|---|
Market Cap | $1.13B | $164.21B |
Sector | Health | Basic Materials |
52-Week High | $5.92 | $218.85 |
52-Week Low | $2.68 | $93.70 |
Enterprise Value | $1.05B | $165.50B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.77, up 4.43% on the day, with a bullish technical signal from moving averages and oscillators despite overbought RSI readings. The company reported a net loss of $244.17 million in 2025, with negative cash flow from operations, but analyst sentiment is strong with 82% buy ratings. Recent news highlights clinical data presentations and a $9.50 consensus price target from brokerages as of July 30, 2026.
The outlook hinges on clinical progress in engineered cell therapies, with upside potential from positive trial outcomes, but risks include persistent cash burn and execution challenges. Investors face high volatility given the pre-revenue biotech profile and dependence on financing activities to sustain operations.
Southern Copper (SCCO) trades at $194.86, down 2.62% on the day, with a bullish technical signal from moving averages and strong support at $191. The company reported record Q2 2026 earnings, beating estimates with EPS of $1.99, driven by high metal prices, though production volumes declined. Revenue and net income have grown consistently, with 2025 revenue at $13.42B and net income at $4.33B, reflecting a net margin of 35.87%.
Outlook remains positive due to robust profitability and AI-driven copper demand, but risks include premium valuation (P/E 29.18), reliance on metal prices, and mixed analyst sentiment with a consensus price target of $153.64 below current levels. Institutional buying and strong cash flow trends support growth, yet investors face volatility from commodity cycles and execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Southern Copper Corp
Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →
